US Cancer Clinics Scramble for Daraxonrasib Access After Trial Doubled Pancreatic Cancer Survival
Updated
Updated · Reuters · May 14
US Cancer Clinics Scramble for Daraxonrasib Access After Trial Doubled Pancreatic Cancer Survival
7 articles · Updated · Reuters · May 14
May 1 FDA expanded access clearance has pushed U.S. cancer centers to start enrolling patients for Revolution Medicines' experimental pancreatic cancer pill daraxonrasib before formal approval.
13.2 months median survival in the trial versus 6.7 months on chemotherapy fueled a surge in demand for the once-daily drug, which targets a mutation seen in about 90% of pancreatic cancers.
Clinics say access is cumbersome: doctors must seek company approval for each patient, then file with the FDA and manage hospital oversight, straining staff and raising concerns about application volume.
Revolution has not said when it will file for full approval, though daraxonrasib was accepted into the FDA's expedited review program and could potentially win a decision within one to two months after submission.
67,000 Americans are expected to be diagnosed with pancreatic cancer this year and 53,000 to die, underscoring why oncologists call the drug a breakthrough even though it is not a cure.
A drug doubles pancreatic cancer survival, but who actually gets it?
This breakthrough cancer drug is free for now, but what will be its real cost?
Is a single pill the future of cancer care, or just the beginning?
Daraxonrasib’s Phase 3 Success: Doubling Survival in Metastatic Pancreatic Cancer and Transforming Treatment Access
Overview
Pancreatic cancer is one of the most challenging cancers, with most patients facing a poor prognosis and many dying within months of diagnosis. Each year, over 50,000 Americans lose their lives to this disease, which accounts for about 8% of all cancer deaths in the U.S. The five-year survival rate is just 13%, and it drops to 3% for those with cancer that has spread. With more than 67,000 new cases expected in 2026, the urgent need for better treatments is clear. This report highlights the immediate impact of new therapies like daraxonrasib, which offer hope for improved outcomes.